CAS No.: 503612-47-3
Product introduction:Apixaban is a potent, orally bioavailable, and highly selective direct inhibitor of coagulation factor Xa. It belongs to the class of direct oral anticoagulants (DOACs) and was developed by Bristol-Myers Squibb and Pfizer. By directly inhibiting factor Xa, apixaban blocks the conversion of prothrombin to thrombin, thereby reducing thrombin generation and thrombus formation. It received its first regulatory approval from the U.S. FDA in 2012 and has since become a widely prescribed alternative to warfarin due to its predictable pharmacokinetics and reduced need for routine monitoring. Apixaban is currently marketed under the brand name Eliquis.
CAS No.:503612-47-3
Apixaban is a white to off-white crystalline powder with the molecular formula C₂₅H₂₅N₅O₄ and a molecular weight of approximately 459.50 g/mol. It is practically insoluble in water but exhibits good solubility in organic solvents such as DMSO. The compound has an oral bioavailability of approximately 50% and reaches peak plasma concentration within 3 to 4 hours of administration. It has a terminal elimination half-life of approximately 12 hours, supporting twice-daily dosing. Apixaban is a substrate of CYP3A4 and P-glycoprotein and should be stored at room temperature, protected from light and moisture.
Core Functions:
Active pharmaceutical ingredient (API) in Eliquis® for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
Treatment and prevention of recurrent deep vein thrombosis and pulmonary embolism
Prophylaxis of venous thromboembolism following hip or knee replacement surgery
Research use in thrombosis and hemostasis studies, including factor Xa inhibition models
Reference standard for analytical method development and quality control in pharmaceutical testing
Contact: Tony
Phone: 008618700976396
E-mail: sales@fulecare.com
Whatsapp:008618700976396
Add: Zhang Ba 6 Road,Hi tech zone,Xi'an Shaanxi Province,China
